Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
14 hedge funds and large institutions have $2.71M invested in Interpace Biosciences, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 5 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
22% less funds holding
Funds holding: 18 → 14 (-4)
27% less capital invested
Capital invested by funds: $3.72M → $2.71M (-$1.01M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$74.4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.06K |
| 3 |
BlackRock
New York
|
+$854 |
| 4 |
LCC
Lincoln Capital Corp
East Greenwich,
Rhode Island
|
+$360 |
| 5 |
Morgan Stanley
New York
|
+$226 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$411K |
| 2 |
VF
Virtu Financial
New York
|
-$133K |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$93K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$11.3K |
IDXG Hedge Fund Activity: Q1 2018 in Review
14 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q1 2018, worth a combined $2.71M — down 27% from $3.72M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IDXG and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $74.4K. The largest seller was Sabby Management, cutting an estimated $411K.
- 14 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q1 2018, down from 18 in Q4 2017.
- Funds reported $2.71M of Interpace Biosciences, Inc. Common Stock stock for Q1 2018, down 27% quarter-over-quarter.
- 1 fund opened new Interpace Biosciences, Inc. Common Stock positions in Q1 2018 and 5 closed out, a net change of -4 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q1 2018 was Vanguard Group, an estimated $74.4K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q1 2018 was Sabby Management, an estimated $411K sold.
Based on aggregated 13F filings for Q1 2018.